{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":22,"n_cols":5,"rows_kept":22,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[11,2,11,3],[12,2,12,3],[13,2,13,3],[14,2,14,3],[16,2,16,3],[17,2,17,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911019785503321"]
[null,null,"Autore",null,"Szabo Gabor Tamas"]
[null,null,"Titolo",null,"Trends in MRNA Vaccine Research"]
[null,null,"Pubbl/distr/stampa",null,"Newark : , : John Wiley & Sons, Incorporated, , 2025"]
[{"$nulls":4},"©2025"]
[null,null,"ISBN",null,"9783527838387"]
[{"$nulls":4},"3527838384"]
[{"$nulls":4},"9783527838394"]
[{"$nulls":4},"3527838392"]
[{"$nulls":4},"9783527838370"]
[{"$nulls":4},"3527838376"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (428 pages)"]
[null,null,"Collana",null,"Trends in Drug Discovery Series"]
[null,null,"Soggetti",null,"COVID-19 vaccines"]
[{"$nulls":4},"Messenger RNA"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Title Page -- Copyright -- Contents -- Preface -- Preface from the Volume Editors -- Part I How mRNA Vaccines Work --   Chapter 1 A Historical Overview on mRNA Vaccine Development --     1.1 Introduction --     1.2 The Path of mRNA as an Unstable and Toxic Product to a New Class of Medicine --       1.2.1 The Discovery and In Vitro Production of mRNA --       1.2.2 The Inflammatory Nature of mRNA --     1.3 How Studying Lipid Bilayer Structures in Cell Membranes Gave Rise to the Eventual Development of Lipid Nanoparticles for RNA Delivery --       1.3.1 From Biological Cell Membranes to Liposomal Drugs --       1.3.2 Ionizable Lipid Nanoparticles for Systemic Delivery of Nucleic Acids --     1.4 The Journey of Developing Clinical mRNA Vaccines --     1.5 Concluding Remarks --     References --   Chapter 2 Immune Responses to mRNA Vaccine --     2.1 Introduction --     2.2 Innate Sensing of RNA Molecules --     2.3 Innate Immune Response to mRNA Vaccines --       2.3.1 Innate Immune Response in Humans --       2.3.2 Tissue Innate Immune Response in Mice --     2.4 mRNA Design and Innate Immunity --       2.4.1 Cap --       2.4.2 Untranslated Regions --       2.4.3 Poly(A) --       2.4.4 Coding Sequence --     2.5 Optimization and Production of "]
[{"$nulls":4},"mRNA for an Adequate Innate Immune Response"]
[null,null,null,"Sommario/riassunto","The authoritative guide to the revolutionary concept behind the successful Covid-19 vaccines   In Trends in mRNA Vaccine Research, a team of distinguished researchers delivers a practical and up-to-date discussion of the biochemical and biomedical foundations of mRNA vaccines. They also explore the manufacturing conditions required for successful vaccine development and review recent progress in a variety of medical fields, including vaccines against pathogens like SARS-CoV-2, HIV, plasmodium, Mycobacterium tuberculosis, as well as anticancer vaccines.   Volume highlights include:    * A historical overview of mRNA vaccine development  * Immune responses to modified or unmodified mRNA vaccines  * A description of the different mRNA vaccine platforms  * Latest data on current mRNA vaccine developments against infectious diseases and cancer  Perfect for medicinal chemists, immunologists, and epidemiologists, Trends in mRNA Vaccine Research will also benefit researchers and scientists working in the pharmaceutical industry, as well as cancer researchers with an interest in vaccine development."]